<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356746</url>
  </required_header>
  <id_info>
    <org_study_id>METC-05/261-E</org_study_id>
    <nct_id>NCT00356746</nct_id>
  </id_info>
  <brief_title>Inflammatory Response During Anesthesia and Surgery</brief_title>
  <acronym>IRAS</acronym>
  <official_title>A Prospective, Randomized Trial to Study the Effects of Different Anesthetic Agents on the Perioperative Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Association of Cardiothoracic Anaesthesiologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of total intravenous anesthesia&#xD;
      versus volatile anesthesia on the perioperative inflammatory response during and after major&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing major surgical procedures, in particular those undergoing cardiac&#xD;
      surgery, develop a severe inflammatory response in up to 50% of cases leading to increased&#xD;
      mortality and morbidity. The inflammatory response depends on the surgical procedure and on&#xD;
      patient related factors like genetic predisposition and co morbidities. However, in vitro&#xD;
      studies showed that the type and duration of general anaesthesia also influences the extent&#xD;
      of perioperative inflammation.&#xD;
&#xD;
      Comparison: total intravenous anesthesia by propofol is compared to volatile anesthesia by&#xD;
      isoflurane with respect to development of perioperative inflammatory response.&#xD;
&#xD;
      The IRAS study is a single centre study, executed in the University Medical Centre Utrecht,&#xD;
      The Netherlands. Four different patient groups are included. 1) Patients undergoing coronary&#xD;
      artery bypass grafting (CABG) with use of cardiopulmonary bypass (CPB), 2) patients&#xD;
      undergoing aorta aneurysm repair via endovascular approach and 3) via conventional open&#xD;
      procedure, and 4) patients undergoing surgery for replacement of implantable cardioverter&#xD;
      defibrillator (ICD).&#xD;
&#xD;
      The IRAS is a prospective, randomized clinical trial. Patients are randomly assigned to a&#xD;
      intravenous or a balanced anaesthesia technique. Peripheral blood samples are drawn before,&#xD;
      during and up to 72h after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perioperative inflammatory response through measurement of expression and responsiveness of Toll-like Receptor (TLR) 2 and 4 of monocytes from full blood samples.</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parameters of systemic haemodynamics</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of vasoactive medication to develop predefined haemodynamic goals</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical parameter of myocardial ischaemia and infarction (Troponin-I), measured immediately before and after surgery, 24 hr and 72hr after surgery</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events assessed 3 days after surgery, at discharge, 30 days and one year after surgery</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>elective CABG only patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>elective ICD replacement surgical patients requiring general anesthesia</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Full blood smaples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        specific surgical patients receiving general anesthesia of university teaching hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years and planned for elective Coronary Artery Bypass Grafting&#xD;
             (CABG), aorta surgery or Implantable Cardioverter Defibrillator (ICD) replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency operations&#xD;
&#xD;
          -  Patients undergoing combined or re-do procedures&#xD;
&#xD;
          -  Patients who are diagnosed with or undergoing treatment for a steroid or hormone&#xD;
             disorder, excluding diabetes&#xD;
&#xD;
          -  Patients suffering from chronic inflammatory diseases&#xD;
&#xD;
          -  Patients suffering form current infections&#xD;
&#xD;
          -  Patients currently treated with steroids&#xD;
&#xD;
          -  Patients undergoing treatment or care for a malignancy&#xD;
&#xD;
          -  Patients participating in another study that may interfere with the endpoints of the&#xD;
             IRAS trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cor J Kalkman, Prof MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Medical Centre Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang F Buhre, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerard Pasterkamp, Prof MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Centre Utrecht, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht, Division of Perioperative Care and Emergency Medicine, Department of Anesthesiology</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res. 2003 Oct 15;60(1):58-67. Review.</citation>
    <PMID>14522407</PMID>
  </reference>
  <reference>
    <citation>de Rossi LW, Brueckmann M, Rex S, Barderschneider M, Buhre W, Rossaint R. Xenon and isoflurane differentially modulate lipopolysaccharide-induced activation of the nuclear transcription factor KB and production of tumor necrosis factor-alpha and interleukin-6 in monocytes. Anesth Analg. 2004 Apr;98(4):1007-1012. doi: 10.1213/01.ANE.0000106860.27791.44.</citation>
    <PMID>15041589</PMID>
  </reference>
  <reference>
    <citation>Larsen B, Hoff G, Wilhelm W, Buchinger H, Wanner GA, Bauer M. Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology. 1998 Nov;89(5):1218-27.</citation>
    <PMID>9822011</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <name_title>WF Buhre</name_title>
    <organization>UMC Utrecht, Department of Anesthesiology</organization>
  </responsible_party>
  <keyword>Perioperative inflammatory response</keyword>
  <keyword>General anesthesia</keyword>
  <keyword>Toll-Like Receptors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

